Form 4: Acadia Pharmaceuticals Director Equity Update

Director Elizabeth A. Garofalo reported the vesting of restricted stock units and the acquisition of new equity awards in Acadia Pharmaceuticals.

Summary

• Director Elizabeth A. Garofalo acquired 8,107 shares of common stock through the vesting of restricted stock units (RSUs) on May 29, 2026.
• The director was granted 16,004 stock options with an exercise price of $21.66, vesting quarterly over one year.
• The director was granted 9,311 RSUs, which are subject to a deferred settlement election.
• Following these transactions, the director holds 33,489 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding director compensation, which does not signal a change in company fundamentals.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Continued long-term commitment evidenced by the deferral of RSU settlement.

Negatives

• None identified; this is a standard compensatory equity filing.

Risks

• Market price volatility affecting the value of granted options and RSUs.
• Potential dilution impact from the issuance of new equity awards.

Future Outlook

The director's equity grants are subject to standard vesting schedules, with options vesting quarterly over one year and RSUs vesting on the earlier of one year or the next annual meeting.

Management Comments

• The reporting person has elected to defer receipt of shares underlying the new RSU grant until specific future events, such as separation from the board or a change in control.

Industry Context

StockSavvy.ai notes that this filing reflects standard annual equity compensation cycles for board members in the biotechnology sector, aimed at retaining independent directors.

Comparison to Industry Standards

• Equity grant sizes and vesting schedules are consistent with standard corporate governance practices for mid-cap pharmaceutical companies.
• The use of deferred settlement for RSUs is a common tax and retention strategy among board members in the industry.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as these are standard compensatory grants.

Next Steps

• Quarterly vesting of stock options over the next 12 months.
• Vesting of 9,311 RSUs on the earlier of one year or the next annual meeting.

Key Dates

Keywords

Acadia Pharmaceuticals, ACAD, Form 4, Insider Trading, Equity Compensation, Director Compensation